• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

氯碳头孢与阿莫西林-克拉维酸治疗急性中耳炎的比较评价

Comparative evaluation of loracarbef and amoxicillin-clavulanate for acute otitis media.

作者信息

Gan V N, Kusmiesz H, Shelton S, Nelson J D

机构信息

Department of Pediatrics, University of Texas, Southwestern Medical Center, Dallas 75235-9063.

出版信息

Antimicrob Agents Chemother. 1991 May;35(5):967-71. doi: 10.1128/AAC.35.5.967.

DOI:10.1128/AAC.35.5.967
PMID:1854178
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC245137/
Abstract

One hundred five infants and children with acute otitis media were randomized to therapy with loracarbef, an experimental carbacephem antibiotic, or amoxicillin-clavulanate (Augmentin), an approved drug for this disease. Ninety-two were evaluable (46 in each group). Middle ear fluid samples obtained for culture before therapy grew Haemophilus spp. in 30% of cases, pneumococci in 29% of cases, and Moraxella catarrhalis in 15% of cases. beta-Lactamase-producing bacteria were found in 37% of patients. Clinical failure occurred in four loracarbef-treated patients and one amoxicillin-clavulanate-treated patient (P = 0.361). Recurrence of acute otitis media was more common in the 2 to 3 weeks after loracarbef treatment (eight patients) than it was after amoxicillin-clavulanate therapy (three patients), but not significantly so (P = 0.197). Thus, combined failure and recurrence occurred in 12 loracarbef-treated patients and four amoxicillin-clavulanate-treated patients (P = 0.052). Gastrointestinal side effects occurred in 13 loracarbef-treated and 21 amoxicillin-clavulanate-treated patients (P = 0.13). Diaper rash was more common with amoxicillin-clavulanate (22 patients) than with loracarbef (10 patients; P = 0.016). Satisfactory results were achieved with both antibiotics, and adverse effects, although common, were minor.

摘要

105名患有急性中耳炎的婴幼儿被随机分为两组,分别接受实验性碳头孢烯类抗生素氯碳头孢或已获批准用于治疗该病的阿莫西林-克拉维酸(安灭菌)治疗。92名患者可进行评估(每组46名)。治疗前获取的中耳积液样本培养结果显示,30%的病例中培养出嗜血杆菌属,29%的病例中培养出肺炎球菌,15%的病例中培养出卡他莫拉菌。37%的患者体内发现产β-内酰胺酶细菌。氯碳头孢治疗组有4名患者临床治疗失败,阿莫西林-克拉维酸治疗组有1名患者临床治疗失败(P = 0.361)。氯碳头孢治疗后2至3周内急性中耳炎复发情况比阿莫西林-克拉维酸治疗后更为常见(氯碳头孢组8例,阿莫西林-克拉维酸组3例),但差异无统计学意义(P = 0.197)。因此,氯碳头孢治疗组共有12例治疗失败和复发,阿莫西林-克拉维酸治疗组有4例(P = 0.052)。氯碳头孢治疗组有13例出现胃肠道副作用,阿莫西林-克拉维酸治疗组有21例出现胃肠道副作用(P = 0.13)。阿莫西林-克拉维酸组尿布疹比氯碳头孢组更常见(阿莫西林-克拉维酸组22例,氯碳头孢组10例;P = 0.016)。两种抗生素均取得了满意的疗效,不良反应虽然常见,但程度较轻。

相似文献

1
Comparative evaluation of loracarbef and amoxicillin-clavulanate for acute otitis media.氯碳头孢与阿莫西林-克拉维酸治疗急性中耳炎的比较评价
Antimicrob Agents Chemother. 1991 May;35(5):967-71. doi: 10.1128/AAC.35.5.967.
2
Loracarbef (LY163892) versus amoxicillin/clavulanate in the treatment of acute purulent bacterial bronchitis.氯碳头孢(LY163892)与阿莫西林/克拉维酸治疗急性化脓性细菌性支气管炎的对比研究
Clin Ther. 1992 Mar-Apr;14(2):166-77.
3
Loracarbef (LY163892) versus amoxicillin/clavulanate in the treatment of acute bacterial exacerbations of chronic bronchitis.氯碳头孢(LY163892)与阿莫西林/克拉维酸治疗慢性支气管炎急性细菌感染的比较
Clin Ther. 1992 Mar-Apr;14(2):214-29.
4
Loracarbef (LY163892) versus amoxicillin-clavulanate in the treatment of bacterial acute otitis media with effusion.
J Pediatr. 1992 Jun;120(6):980-6. doi: 10.1016/s0022-3476(05)81974-2.
5
Loracarbef (LY163892) versus amoxicillin/clavulanate in bronchopneumonia and lobar pneumonia.氯碳头孢(LY163892)与阿莫西林/克拉维酸治疗支气管肺炎和大叶性肺炎的比较
Clin Ther. 1992 Mar-Apr;14(2):254-67.
6
Comparative trial of cefprozil vs. amoxicillin clavulanate potassium in the treatment of children with acute otitis media with effusion.头孢丙烯与阿莫西林克拉维酸钾治疗儿童急性分泌性中耳炎的对比试验
Pediatr Infect Dis J. 1991 May;10(5):375-80. doi: 10.1097/00006454-199105000-00006.
7
Comparative efficacy and safety of cefprozil and amoxycillin/clavulanate in the treatment of acute otitis media in children.头孢丙烯与阿莫西林/克拉维酸治疗儿童急性中耳炎的疗效和安全性比较
J Antimicrob Chemother. 1994 Jun;33(6):1209-18. doi: 10.1093/jac/33.6.1209.
8
Multi-investigator evaluation of the efficacy and safety of cefprozil, amoxicillin-clavulanate, cefixime and cefaclor in the treatment of acute otitis media.多位研究者对头孢丙烯、阿莫西林-克拉维酸、头孢克肟和头孢克洛治疗急性中耳炎的疗效和安全性进行的评估。
Eur J Clin Microbiol Infect Dis. 1994 Oct;13(10):857-65. doi: 10.1007/BF02111353.
9
Comparative treatment trial of augmentin versus cefaclor for acute otitis media with effusion.阿莫西林克拉维酸钾与头孢克洛治疗急性分泌性中耳炎的对比治疗试验。
Pediatrics. 1985 May;75(5):819-26.
10
Acute otitis media in children: a study of nasopharyngeal carriage of potential pathogens and therapeutic efficacy of cefixime and amoxicillin-clavulanate.儿童急性中耳炎:潜在病原体的鼻咽部携带情况及头孢克肟与阿莫西林-克拉维酸治疗效果的研究
Infection. 1995;23 Suppl 2:S79-82. doi: 10.1007/BF01742989.

引用本文的文献

1
Quantitative detection of Moraxella catarrhalis in nasopharyngeal secretions by real-time PCR.通过实时聚合酶链反应对鼻咽分泌物中卡他莫拉菌进行定量检测。
J Clin Microbiol. 2003 Apr;41(4):1386-90. doi: 10.1128/JCM.41.4.1386-1390.2003.
2
Lipooligosaccharide P(k) (Galalpha1-4Galbeta1-4Glc) epitope of moraxella catarrhalis is a factor in resistance to bactericidal activity mediated by normal human serum.卡他莫拉菌的脂寡糖P(k)(半乳糖α1-4半乳糖β1-4葡萄糖)表位是抵抗正常人血清介导的杀菌活性的一个因素。
Infect Immun. 2000 Sep;68(9):5261-8. doi: 10.1128/IAI.68.9.5261-5268.2000.
3
Mapping of a protective epitope of the CopB outer membrane protein of Moraxella catarrhalis.卡他莫拉菌CopB外膜蛋白保护性表位的定位
Infect Immun. 1998 Feb;66(2):540-8. doi: 10.1128/IAI.66.2.540-548.1998.
4
Branhamella catarrhalis: epidemiology, surface antigenic structure, and immune response.卡他布兰汉菌:流行病学、表面抗原结构及免疫反应
Microbiol Rev. 1996 Jun;60(2):267-79. doi: 10.1128/mr.60.2.267-279.1996.
5
Expression of the CopB outer membrane protein by Moraxella catarrhalis is regulated by iron and affects iron acquisition from transferrin and lactoferrin.卡他莫拉菌CopB外膜蛋白的表达受铁调节,并影响从转铁蛋白和乳铁蛋白获取铁。
Infect Immun. 1996 Jun;64(6):2024-30. doi: 10.1128/iai.64.6.2024-2030.1996.
6
Loracarbef. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy.氯碳头孢。对其抗菌活性、药代动力学特性及治疗效果的综述。
Drugs. 1993 May;45(5):716-36. doi: 10.2165/00003495-199345050-00008.

本文引用的文献

1
Emergence of beta-lactamase-producing strains of Branhamella catarrhalis as important agents of acute otitis media.产β-内酰胺酶的卡他莫拉菌菌株成为急性中耳炎的重要病原体。
Pediatr Infect Dis. 1983 Jan-Feb;2(1):34-8. doi: 10.1097/00006454-198301000-00009.
2
beta-Lactamase-producing Branhamella catarrhalis causing otitis media in children.产β-内酰胺酶的卡他布兰汉菌导致儿童中耳炎。
J Pediatr. 1983 Feb;102(2):261-4. doi: 10.1016/s0022-3476(83)80537-x.
3
Five vs. ten days of therapy for acute otitis media.急性中耳炎治疗5天与10天的对比
Pediatr Infect Dis J. 1988 Jan;7(1):14-23. doi: 10.1097/00006454-198801000-00005.
4
Pharmacokinetics of LY163892 in infants and children.LY163892在婴幼儿和儿童中的药代动力学。
Antimicrob Agents Chemother. 1988 Nov;32(11):1738-9. doi: 10.1128/AAC.32.11.1738.
5
In vitro susceptibilities of common pediatric pathogens to LY163892.常见儿科病原体对LY163892的体外敏感性
Antimicrob Agents Chemother. 1988 Feb;32(2):268-70. doi: 10.1128/AAC.32.2.268.